Chemomab Therapeutics Ltd. CMMB
Biotechnology: Pharmaceutical Preparations · IPO 2019 · data as of November 13, 2026
Chemomab Therapeutics Ltd. (CMMB) is a healthcare company listed in the US with a market value of about $12M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -826%.
About Chemomab Therapeutics
Chemomab Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2019. It was profitable in 0 of the last 10 years in our data.
Score: 0.8 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Net income | -$9M | -$14M | -$24M | -$28M | -$12M | -$6M | -$27M | -$14M | -$10M | -$5M |
| Free cash flow | -$11M | -$15M | -$24M | -$20M | -$13M | -$5M | -$17M | -$14M | -$9M | -$4M |
| EPS (diluted) | $-1.12 | $-1.73 | $-3.01 | $-3.43 | $-1.55 | $-0.74 | $-3.37 | $-1.71 | $-1.22 | $-0.59 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | -908.1% | -743.1% | — | — | — | — | — | -110.6% | — | -111.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Chemomab Therapeutics pay a dividend?
Not currently.
Is Chemomab Therapeutics a good stock to buy?
We do not give buy or sell advice. Chemomab Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.